Your browser doesn't support javascript.
loading
Metabolic Health in Short Children Born Small for Gestational Age Treated With Growth Hormone and Gonadotropin-Releasing Hormone Analog: Results of a Randomized, Dose-Response Trial.
van der Steen, Manouk; Lem, Annemieke J; van der Kaay, Danielle C M; Bakker-van Waarde, Willie M; van der Hulst, Flip J P C M; Neijens, Floor S; Noordam, Cees; Odink, Roelof J; Oostdijk, Wilma; Schroor, Eelco J; Westerlaken, Ciska; Hokken-Koelega, Anita C S.
Afiliação
  • van der Steen M; Dutch Growth Research Foundation (M.v.d.S., A.J.L., D.C.M.v.d.K., A.C.S.H.K.), Rotterdam, 3001 KB, The Netherlands; Children's Hospital Erasmus MC-Sophia (M.v.d.S., A.C.S.H.K.), 3000 CA, Rotterdam, The Netherlands; Department of Pediatrics (W.M.B.v.W.), University Medical Center Groningen, 9700 RB G
  • Lem AJ; Dutch Growth Research Foundation (M.v.d.S., A.J.L., D.C.M.v.d.K., A.C.S.H.K.), Rotterdam, 3001 KB, The Netherlands; Children's Hospital Erasmus MC-Sophia (M.v.d.S., A.C.S.H.K.), 3000 CA, Rotterdam, The Netherlands; Department of Pediatrics (W.M.B.v.W.), University Medical Center Groningen, 9700 RB G
  • van der Kaay DC; Dutch Growth Research Foundation (M.v.d.S., A.J.L., D.C.M.v.d.K., A.C.S.H.K.), Rotterdam, 3001 KB, The Netherlands; Children's Hospital Erasmus MC-Sophia (M.v.d.S., A.C.S.H.K.), 3000 CA, Rotterdam, The Netherlands; Department of Pediatrics (W.M.B.v.W.), University Medical Center Groningen, 9700 RB G
  • Bakker-van Waarde WM; Dutch Growth Research Foundation (M.v.d.S., A.J.L., D.C.M.v.d.K., A.C.S.H.K.), Rotterdam, 3001 KB, The Netherlands; Children's Hospital Erasmus MC-Sophia (M.v.d.S., A.C.S.H.K.), 3000 CA, Rotterdam, The Netherlands; Department of Pediatrics (W.M.B.v.W.), University Medical Center Groningen, 9700 RB G
  • van der Hulst FJ; Dutch Growth Research Foundation (M.v.d.S., A.J.L., D.C.M.v.d.K., A.C.S.H.K.), Rotterdam, 3001 KB, The Netherlands; Children's Hospital Erasmus MC-Sophia (M.v.d.S., A.C.S.H.K.), 3000 CA, Rotterdam, The Netherlands; Department of Pediatrics (W.M.B.v.W.), University Medical Center Groningen, 9700 RB G
  • Neijens FS; Dutch Growth Research Foundation (M.v.d.S., A.J.L., D.C.M.v.d.K., A.C.S.H.K.), Rotterdam, 3001 KB, The Netherlands; Children's Hospital Erasmus MC-Sophia (M.v.d.S., A.C.S.H.K.), 3000 CA, Rotterdam, The Netherlands; Department of Pediatrics (W.M.B.v.W.), University Medical Center Groningen, 9700 RB G
  • Noordam C; Dutch Growth Research Foundation (M.v.d.S., A.J.L., D.C.M.v.d.K., A.C.S.H.K.), Rotterdam, 3001 KB, The Netherlands; Children's Hospital Erasmus MC-Sophia (M.v.d.S., A.C.S.H.K.), 3000 CA, Rotterdam, The Netherlands; Department of Pediatrics (W.M.B.v.W.), University Medical Center Groningen, 9700 RB G
  • Odink RJ; Dutch Growth Research Foundation (M.v.d.S., A.J.L., D.C.M.v.d.K., A.C.S.H.K.), Rotterdam, 3001 KB, The Netherlands; Children's Hospital Erasmus MC-Sophia (M.v.d.S., A.C.S.H.K.), 3000 CA, Rotterdam, The Netherlands; Department of Pediatrics (W.M.B.v.W.), University Medical Center Groningen, 9700 RB G
  • Oostdijk W; Dutch Growth Research Foundation (M.v.d.S., A.J.L., D.C.M.v.d.K., A.C.S.H.K.), Rotterdam, 3001 KB, The Netherlands; Children's Hospital Erasmus MC-Sophia (M.v.d.S., A.C.S.H.K.), 3000 CA, Rotterdam, The Netherlands; Department of Pediatrics (W.M.B.v.W.), University Medical Center Groningen, 9700 RB G
  • Schroor EJ; Dutch Growth Research Foundation (M.v.d.S., A.J.L., D.C.M.v.d.K., A.C.S.H.K.), Rotterdam, 3001 KB, The Netherlands; Children's Hospital Erasmus MC-Sophia (M.v.d.S., A.C.S.H.K.), 3000 CA, Rotterdam, The Netherlands; Department of Pediatrics (W.M.B.v.W.), University Medical Center Groningen, 9700 RB G
  • Westerlaken C; Dutch Growth Research Foundation (M.v.d.S., A.J.L., D.C.M.v.d.K., A.C.S.H.K.), Rotterdam, 3001 KB, The Netherlands; Children's Hospital Erasmus MC-Sophia (M.v.d.S., A.C.S.H.K.), 3000 CA, Rotterdam, The Netherlands; Department of Pediatrics (W.M.B.v.W.), University Medical Center Groningen, 9700 RB G
  • Hokken-Koelega AC; Dutch Growth Research Foundation (M.v.d.S., A.J.L., D.C.M.v.d.K., A.C.S.H.K.), Rotterdam, 3001 KB, The Netherlands; Children's Hospital Erasmus MC-Sophia (M.v.d.S., A.C.S.H.K.), 3000 CA, Rotterdam, The Netherlands; Department of Pediatrics (W.M.B.v.W.), University Medical Center Groningen, 9700 RB G
J Clin Endocrinol Metab ; 100(10): 3725-34, 2015 Oct.
Article em En | MEDLINE | ID: mdl-26259134
ABSTRACT
CONTEXT Previously we showed that pubertal children born small for gestational age (SGA) with a poor adult height (AH) expectation can benefit from treatment with GH 1 mg/m(2) per day (∼ 0.033 mg/kg/d) in combination with 2 years of GnRH analog (GnRHa) and even more so with a double GH dose. GnRHa treatment is thought to have negative effects on body composition and blood pressure. Long-term effects and GH-dose effects on metabolic health in children treated with combined GH/GnRHa are unknown.

OBJECTIVE:

This study aimed to investigate body composition, blood pressure, and lipid profile during GH treatment, either with or without 2 years of additional GnRHa. To assess whether GH 2 mg/m(2) per day (∼ 0.067 mg/kg/d) results in a similar or even more favorable metabolic health at AH than GH 1 mg/m(2) per day.

METHODS:

This was a longitudinal, randomized, dose-response GH trial involving 107 short SGA children (58 girls) treated with GH until AH (GH randomized 1 or 2 mg/m(2)/d during puberty). Sixty-four children received additional GnRHa. At AH, metabolic parameters were compared between children treated with combined GH/GnRHa and those with only GH. The GH dose effect on metabolic health was evaluated in a subgroup of 47 children who started GH treatment in early puberty (randomized 1 or 2 mg/m(2)/d) with 2 years of GnRHa.

RESULTS:

At AH, fat mass percentage (FM%) SD score (SDS), lean body mass (LBM) SDS, blood pressure SDS, and lipid profile were similar between children treated with combined GH/GnRHa and those with only GH. In the pubertal subgroup, FM% SDS was lower during treatment with GH 2 mg/m(2) per day. There was no GH dose-dependent effect on LBM SDS, blood pressure, and lipid profile.

CONCLUSIONS:

Combined GH/GnRHa treatment has no long-term negative effects on metabolic health compared with only GH. Started in early puberty, a GH dose of 2 mg/m(2) per day results in a similar metabolic health at AH and a more favorable FM% than GH 1 mg/m(2) per day.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Composição Corporal / Estatura / Leuprolida / Hormônio do Crescimento Humano / Transtornos do Crescimento Tipo de estudo: Clinical_trials Limite: Adolescent / Child / Female / Humans / Male Idioma: En Revista: J Clin Endocrinol Metab Ano de publicação: 2015 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Composição Corporal / Estatura / Leuprolida / Hormônio do Crescimento Humano / Transtornos do Crescimento Tipo de estudo: Clinical_trials Limite: Adolescent / Child / Female / Humans / Male Idioma: En Revista: J Clin Endocrinol Metab Ano de publicação: 2015 Tipo de documento: Article